摘要: Lilly is developing the racemic compound LY-215490, a selective and competitive AMPA antagonist, as potential treatment for cerebral infarction, cerebrovascular ischemia, epilepsy an analgesic [135089], [158980], [254029], [278691]. By January 2000, LY-293558 was undergoing phase II trials pain [414000].
参考文章(0)